pharmaphorum7d
Civica plans shake-up of insulin sector with low-cost biosimilars
The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine ... prices of the originator insulin are around $329 per vial and $510 for five pens, according to ...
pharmaphorum5d
Sanofi turns the tables on Lilly with biosimilar fast-acting insulin
But it looks unlikely that Lilly will be able to maintain this with the launch of Humalog, which is available in vial ... acting insulin market with a cheaper version of Sanofi’s Lantus (insulin ...
What consumers should know about the FTC’s upcoming lawsuit against CVS over how it negotiates drug prices
A vial of insulin costs about $8 to manufacture, researchers estimate. But Sanofi’s Lantus costs $292 per vial, Nordisk’s ...
Benzinga.com24d
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting ... to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78%.
Medscape2d
Room-temperature Storage of Medications Labeled for Refrigeration
28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...
Business Insider India2y
There's something odd about the way insulin prices change
A 10 ml vial of Sanofi's long-acting insulin Lantus first hit the US market at $34.81 a vial in 2001, according to data from Truven Health Analytics. Since 2014, the last time Sanofi raised the ...